Skip to main content
LXEO
NASDAQ Life Sciences

LX2020 Cuts Arrhythmia Burden 80% in High-Dose Cohorts; FDA Open to NSVT Endpoint

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.85
Mkt Cap
$235.593M
52W Low
$2.55
52W High
$10.99
52W Position info
12% above low
Off High info
74% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

LXEO is trading near its 52-week low of $2.55 (12% above the low) on light trading volume (0.3× avg).

Summary

Lexeo's LX2020 gene therapy cut non-sustained ventricular tachycardia burden by a mean 80% and PVCs by 44% in the seven high-dose participants at latest assessment, with six of seven showing NSVT improvement. Safety held up across all ten dosed patients: no clinically significant complement activation, no discontinuations, and the one previously disclosed Grade 3 VT event resolved with anti-arrhythmic medication. The bigger news is regulatory — the FDA is open to guideline-defined NSVT as a primary surrogate endpoint for an accelerated approval pivotal study, with final design and statistical analysis plan expected in 1H 2027 and study start in 2H 2027. That gives a credible path to filing for a program with no approved therapy, though the design is still subject to further FDA discussion. Cash of $219.1M funds operations into 2028, but the Q3 net loss widened to $38.3M ($0.43 per share) from $20.3M a year ago on $34.5M of R&D, much of it one-time Mantle acquisition and LX2006 milestone costs. This is a separate program from the LX2006 interim data reported November 2nd; the company also added former Crinetics CFO Toby Schilke to its board.

At the time of this announcement, LXEO was trading at $2.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $235.6M. The 52-week trading range was $2.55 to $10.99. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LXEO - Latest Insights

LXEO
Nov 16, 2026, 7:05 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.20
Real-time Price: $3.94 info
Change: +$0.740 (+23%) info
Market Cap: $235.593M info
LXEO
Nov 16, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $3.94 info
Change: +$0.950 (+32%) info
Market Cap: $235.593M info
LXEO
Nov 02, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.14
Real-time Price: $3.94 info
Change: +$0.800 (+25%) info
Market Cap: $235.593M info
LXEO
Sep 22, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.84
Real-time Price: $3.94 info
Change: +$0.096 (+2%) info
Market Cap: $235.593M info
LXEO
Sep 22, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.18
Real-time Price: $3.94 info
Change: -$0.240 (-6%) info
Market Cap: $235.593M info